Funding Opportunity – NHLBI Catalyze Program

The National Heart, Lung, and Blood Institute (NHLBI) Catalyze Program is soliciting applications for early stage translational research projects with the goal of developing basic scientific discoveries into viable therapeutics, devices, and diagnostics to treat heart, lung, blood, and sleep diseases and disorders.

Funding is available for early stage technology development, including:

Therapeutics (Small molecules/Biologics)
– Identifying and characterizing lead compounds

Devices/Diagnostics/Tools
– Developing, testing, and modifying prototypes
– Identifying and developing assay targets
– Developing research tools

Enabling Technologies and Transformative Platforms
– Developing highly-innovative, next-generation technologies that could transform current approaches to clinical practice or translational research (technology must be beyond proof-of-concept and should be ready to begin validation)
– Accelerating the areas of early detection and screening, animal model development, or clinical diagnosis

Learn more about the program and the informational webinar taking place on October 3, 2019 on the NHLBI website.

CFB to Host BARDA Industry Day Hybrid Event – 10/15

As an BARDA DRIVe accelerator, the CFB will be hosting hybrid viewing event of BARDA Industry Day for those who can’t make it to Washington to participate in the event. We’ll be streaming the plenary sessions and other exciting content from Day 1 of BARDA Industry Day on October 15, 2019. To learn more about the event, please visit the Industry Day website.

To join the virtual viewing event RSVP with the CFB here: https://bid-2019-cfb.eventbrite.com/

Funding Opportunity: Long Island Bioscience Hub REACH

The Center for Biotechnology, on behalf of Long Island Bioscience Hub (LIBH), is pleased to announce the opening of the 8th round of the LIBH Technology Development RFP.

Two specific funding programs have been designed to help faculty, physicians, surgeons, medical fellows, and post-docs develop their academic innovations toward commercial goals. The RFP is and forms for the funding programs can be found on the Center for Biotechnology website here.

Those interested in applying are strongly encouraged to discuss the proposal with:
Anton Xavier (anton.xavier@stonybrook.edu)
William Hanes (william.hanes@stonybrook.edu)
Heather Bielski Lawler (heather.bielski@stonybrook.edu)
Johnna St Clair (johnna.stclair@stonybrook.edu)

They are happy to introduce this Technology Development program and provide support to address unfamiliar questions in the application.

Deadline for submission is Sep 13th, 2019. All proposal should be submitted through the online portal HERE. Please note an approval from your Sponsored Programs Office is NOT required prior to the submission but will be required if the project is selected for NIH secondary review. Eligible applicants will be notified if their application is selected to move forward.

The Center for Biotechnology, in collaboration with Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute for Medical Research, formed the LIBH. A principal goal of the LIBH is to foster the development of therapeutics, diagnostics, devices and research tools emerging from within the four partner institutions that address diseases within the mission of NIH. The LIBH is supported by the National Institutes of Health REACH initiative (Research Evaluation and Commercialization Hub), our four partner institutions, The Research Foundation for SUNY, and Empire State Development.

 

DEADLINE EXTENDED! NIH SBIR/STTR Commercialization Accelerator Program (CAP)

Due to a few technical difficulties, and to accommodate new and/or incoming awardees, NIH is extending the deadline to apply to their NIH Commercialization Accelerator Program (NIH CAP).

The new deadline is 11:59 p.m. PDT (Pacific) FRIDAY, September 13, 2019.

This is a cost free* customized commercialization (market readiness/growth) program. For 16 years, CAP has provided customized technical/business assistance to companies at different stages, and has a notable track record: 50 acquisitions (including companies acquired by Sony, Zoll, Bruker, BioMarin, Illumina, Takeda, Google, Roche, etc.), 10 IPOs, and more than $1B in 3rd party funding raised.

The program features:

  • world-class guidance from experienced domain professionals, including industry and technical specialists affiliated with Bayer Healthcare, Qualcomm, Baxter, Pfizer, Genetech, McKesson, Medtronic, CMS, Life Technology, etc.
  • Feedback and interaction from a range of stakeholders in the life sciences marketplace
  • Notable graduates of the CAP include: Sharklet, Lift Labs, (provide a few big and recognizable names)
  • Alumni benefit – Continued access to Larta’s network and resources post program!

*CAP participation is free of charge for program participating companies; however, participants are responsible for travel and lodging expenses associated with attending workshops and program related events.

For more details on this program, including success data, eligibility and instructions, please visit: https://sbir.nih.gov/cap.

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Deadlines

The newly re-authorized Commercialization Readiness Pilot (CRP) program is now accepting applications from previously or currently HHS-funded SBIR and STTR Phase II and Phase IIB awardees.

NHLBI open and accepting applications from NHLBI grantees for the September 5th NIH SBIR/STTR receipt date; HHS/NIH general applications will be accepted from August 5, 2019 until April 6, 2022 via standard due dates.

CPR can provide over $3 million in additional funding to facilitate the commercialization transition for projects, and support work that is not typically supported through SBIR/STTR Phase II or Phase IIB awards, including:

– Preparation of documents for a Food and Drug Administration (FDA) submission
– Development of an intellectual property strategy
– Investigational New Drug (IND)-enabling studies
– Clinical studies
– Manufacturing costs
– Regulatory assistance
– Subcontracted work to other institutions, including contract research organizations (CRO)
– A combination of services.

Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&D throughout the award. Please note, this re-authorization includes (3) separate Funding Opportunity Announcements (FOAs) with varying participating NIH Institutes and Centers. Learn more here: https://sbir.nih.gov/funding#crp